MindMed Begins Phase 3 LSD Study for Anxiety
Mind Medicine (MNMD) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Mind Medicine has commenced its Phase 3 Voyage study, dosing the first patient with MM120, an optimized form of LSD, for treating Generalized Anxiety Disorder (GAD). This study aims to assess the drug’s efficacy and safety compared to a placebo, building on promising Phase 2b results. The company plans to enroll approximately 200 participants in the U.S., with a second trial set to start in 2025 in the U.S. and Europe.
For further insights into MNMD stock, check out TipRanks’ Stock Analysis page.
Trending Articles
TipRanks is the most comprehensive data set of sell side analysts and hedge fund managers. TipRanks' multi-award winning platform ranks financial experts based on measured performance and the accuracy of their predictions so investors know who to trust when making investment decisions.